Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B - Pasi, K John; Fischer, Kathelijn; Ragni, Margaret; Nolan, Beatrice; Perry, David J; Kulkarni, Roshni; Ozelo, Margareth; Mahlangu, Johnny; Shapiro, Amy D; Baker, Ross I; Bennett, Carolyn M; Barnes, Christopher; et al. (Thrombosis and haemostasis, 2017)
Keywords: Adolescent; Adult; Antibodies, Neutralizing - blood; Child; Coagulants - administration & dosage; Coagulants - adverse effects; Drug Administration Schedule; Factor IX - administration & dosage; Factor IX - adverse effects; Factor IX - immunology; Hemophilia B - blood; Hemophilia B - diagnosis; Hemophilia B - drug therapy; Hemorrhage - blood; Hemorrhage - prevention & control; Hemostasis - drug effects; Humans; Immunoglobulin Fc Fragments - administration & dosage; Immunoglobulin Fc Fragments - adverse effects; Immunoglobulin Fc Fragments - immunology; Male; Middle Aged; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - immunology; Risk Factors; Time Factors; Treatment Outcome; Young Adult; haemophilia; Factor IX; recombinant fusion proteins; prophylaxis